A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution

Masterson, Wylie; Brown, Alexandria; Ameri, May A. Al; Patel, Anisha B.

doi:10.1016/j.ctarc.2021.100506

Cited by 4 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The occurrence of cirAEs is correlated with survival, 4 but clinical significance of a re‐emergent cirAE is unclear. LD cirAEs have been reported to persist months beyond ICI cessation 5 . In summary, presentation of a penile ulcer should prompt inclusion of LD on the differential diagnosis in a patient undergoing immunotherapy.…”

Section: Figurementioning

confidence: 97%

“…LD cirAEs have been reported to persist months beyond ICI cessation. 5 In summary, presentation of a penile ulcer should prompt inclusion of LD on the differential diagnosis in a patient undergoing immunotherapy. Furthermore, mucocutaneous LD ci-rAEs may present months after starting ICI, may recur post-cessation of ICI (re-emergent cirAE), and may also include geographic tongue.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Nivolumab‐induced lichenoid penile ulceration and re‐emergent mucocutaneous eruption treated with hydroxychloroquine

Headd,

Mathien,

Pei

et al. 2024

Aust J Dermatology

View full text Add to dashboard Cite

Section: Figurementioning

confidence: 97%

mentioning

confidence: 99%

Nivolumab‐induced lichenoid penile ulceration and re‐emergent mucocutaneous eruption treated with hydroxychloroquine

Headd,

Mathien,

Pei

et al. 2024

Aust J Dermatology

View full text Add to dashboard Cite

“…In patients with grade-3 disease, systemic steroids (0.5–1 mg kg/day) are recommended. Retinoids (acitretin 10–30 mg/day), methotrexate, and azathioprine treatments can be considered in refractory cases based on case series and reports ( Table 1 ) [ 52 ]. UVB-NB can also be used with the precautions already discussed for melanoma patients.…”

Section: Cutaneous Immune-related Adverse Eventsmentioning

confidence: 99%

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma

Nikolaou

Tsimpidakis

Stratigos

2023

Cancers

View full text Add to dashboard Cite

Immune checkpoint blockers (ICBs) have been widely used during the last decade for the treatment of various tumors, including advanced and metastatic melanoma. While these agents have improved melanoma patients’ survival rates, they have also been associated with various autoimmune toxicities, with the skin being most commonly affected. The severity of cutaneous toxicity can not only negatively affect patients’ quality of life but can also limit the proper treatment of cancer. Thus, the role of the dermatologist is substantial in early detecting and promptly treating these adverse events. Maculopapular rash, psoriasiform, lichenoid dermatoses and bullous pemphigoid are the most frequent cutaneous adverse events that require immediate intervention. Other rare autoimmune toxicities, e.g., sarcoidosis, dermatomyositis or subacute lupus, have also been reported. In this review, we summarize the aspects of ICB-induced cutaneous toxicities in patients with melanoma, emphasizing their management and treatment options in clinical practice.

show abstract

“…Acitretin is a systemic vitamin A derivative (retinoid) that is FDA-approved for the treatment of psoriasis. It is also used frequently in psoriasis, psoriasiform, or lichenoid eruptions induced by systemic cancer treatments, including ICIs, and is recommended by the NCCN for moderate psoriasiform ircAEs and severe lichenoid ircAEs [3,82,[87][88][89].…”

Section: Acitretinmentioning

confidence: 99%

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events

Gu,

Nath,

Markova

2023

Pharmaceuticals

View full text Add to dashboard Cite

Immune-related cutaneous adverse events (ircAEs) commonly occur in patients on treatment with immune checkpoint inhibitors and can significantly reduce patient quality of life. These are often treated with immunomodulatory agents, including glucocorticoids, immunosuppressants, and biologics. While often effective at managing symptoms, these therapies can cause several adverse events which may limit their use. In addition, immunomodulatory agents should be used with particular caution in patients receiving immunotherapy, as the efficacy of the oncologic regimen may potentially be undermined. In this review, we summarize the safety of systemic therapies that are used in the management of ircAEs, with a particular focus on the resultant risk of secondary tumor progression in patients with active cancer.

show abstract

A retrospective chart review of management strategies for lichenoid eruptions associated with immune-checkpoint inhibitor therapy from a single institution

Cited by 4 publications

References 18 publications

Nivolumab‐induced lichenoid penile ulceration and re‐emergent mucocutaneous eruption treated with hydroxychloroquine

Nivolumab‐induced lichenoid penile ulceration and re‐emergent mucocutaneous eruption treated with hydroxychloroquine

Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma

Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events

Contact Info

Product

Resources

About